deltatrials
Completed PHASE4 NCT00189293

Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts

Multicenter, Randomised, Double-blind, Vehicle-controlled Study Comparing Recurrence Rate Following Imiquimod 5% Cream or Vehicle 3 Times Per Week for 4 Weeks Prior to Ablative Therapy in Subjects Suffering From External Ano-Genital Warts

Sponsor: MEDA Pharma GmbH & Co. KG

Conditions Genital Warts
Interventions Imiquimod vehicle cream
Updated 7 times since 2017 Last updated: Feb 4, 2022 Started: Jun 30, 2005 Primary completion: Dec 31, 2007 Completion: Dec 31, 2007

Listed as NCT00189293, this PHASE4 trial focuses on Genital Warts and remains completed. Sponsored by MEDA Pharma GmbH & Co. KG, it has been updated 7 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Mar 2022 — Jul 2024 [monthly]

    Completed PHASE4

  5. Jan 2021 — Mar 2022 [monthly]

    Completed PHASE4

▶ Show 2 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE4

    First recorded

Jun 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • MEDA Pharma GmbH & Co. KG
Data source: Viatris Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ancona, Italy, Asti, Italy, Bari, Italy, Catania, Italy, Florence, Italy, Genova, Italy, Milan, Italy, Modena, Italy, Palermo, Italy, Pozzuoli, Italy and 1 more location